PS1248 COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL

Background: Despite the improvement in therapeutic schedules, a relevant fraction of mantle cell lymphoma (MCL) patients still experience primary treatment failure. This is due to a deep biological heterogeneity, not adequately dissected by the clinical predictors alone, as the MIPI (MCL Internation...

Full description

Saved in:
Bibliographic Details
Published in:HemaSphere 2019-06, Vol.3 (S1), p.569-570
Main Authors: Ferrero, S., Zaccaria, G.M., Barbero, D., Evangelista, A., Rocco, A., Re, A., Stefoni, V., Cavallo, F., Vitolo, U., Balzarotti, M., Rusconi, C., Silva, M. Gomes, Ghislieri, M., Omedè, P., Zamò, A., Ciccone, G., Gattei, V., Gaidano, G., Cortelazzo, S., Ladetto, M.
Format: Article
Language:English
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Despite the improvement in therapeutic schedules, a relevant fraction of mantle cell lymphoma (MCL) patients still experience primary treatment failure. This is due to a deep biological heterogeneity, not adequately dissected by the clinical predictors alone, as the MIPI (MCL International Prognostic Index). Aims: The Fondazione Italiana Linfomi (FIL) MCL0208 trial (NCT02354313) is a prospective, randomized phase III trial comparing lenalidomide maintenance vs observation after an intensive citarabine containing chemo‐immunotherapy followed by autologous transplantation in frontline MCL patients
ISSN:2572-9241
2572-9241
DOI:10.1097/01.HS9.0000563272.02759.6b